Elterman D, Kaplan SA. Reimagining male lower urinary tract symptoms due to benign prostatic hyperplasia treatment: a new approach to first-line interventional therapy. Eur Urol Focus. 2025. https://doi.org/10.1016/j.euf.2024.12.008.

Malde S, Umbach R, Wheeler JR, Lytvyn L, Cornu JN, Gacci M, et al. A systematic review of patients’ values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms. Eur Urol. 2021;79:796–809. https://doi.org/10.1016/j.eururo.2020.12.019.

Article  PubMed  Google Scholar 

De Nunzio C, Presicce F, Lombardo R, Trucchi A, Bellangino M, Tubaro A, et al. Patient centred care for the medical treatment of lower urinary tract symptoms in patients with benign prostatic obstruction: a key point to improve patients’ care - A systematic review. BMC Urol. 2018;18:62. https://doi.org/10.1186/s12894-018-0376-x.

Article  PubMed  PubMed Central  Google Scholar 

Gravas S, Malde S, Cornu JN, Gacci M, Gratzke C, Herrmann TRW, et al. From BPH to male LUTS: a 20-year journey of the EAU guidelines. Prostate Cancer Prostatic Dis. 2023;27:48–53. https://doi.org/10.1038/s41391-023-00700-3.

Article  PubMed  Google Scholar 

Chughtai B, Rojanasarot S, Neeser K, Gultyaev D, Fu S, Bhattacharyya SK, et al. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS One. 2022;17:e0266824. https://doi.org/10.1371/journal.pone.0266824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wymer KM, Narang G, Slade A, Sharma V, Thao V, Borah BJ, et al. Evaluation of the cost-effectiveness of surgical treatment options for Benign prostatic hyperplasia. Urology. 2023;171:96–102. https://doi.org/10.1016/j.urology.2022.09.026.

Article  PubMed  Google Scholar 

Baboudjian M, Cornu JN, Gondran-Tellier B, Fourmarier M, Robert G, Peyronnet B, et al. Pharmacologic and surgical retreatment after office-based treatments for benign prostatic hyperplasia: a systematic review. Eur Urol Focus. 2023;9:727–33. https://doi.org/10.1016/j.euf.2023.03.004.

Article  PubMed  Google Scholar 

Ditonno F, Manfredi C, Licari LC, Bologna E, Franco A, Pandolfo SD, et al. Benign prostatic hyperplasia surgery: a snapshot of trends, costs, and surgical retreatment rates in the USA. Eur Urol Focus. 2024;10:826–32. https://doi.org/10.1016/j.euf.2024.04.006.

Article  PubMed  Google Scholar 

Kaplan S, Kaufman RP, Mueller T, Elterman D, Chughtai B, Rukstalis D, et al. Retreatment rates and postprocedural complications are higher than expected after BPH surgeries: a US healthcare claims and utilization study. Prostate Cancer Prostatic Dis. 2024;27:485–91. https://doi.org/10.1038/s41391-023-00741-8.

Article  PubMed  Google Scholar 

Ayangbesan A, Kavoussi N. Racial disparities in diagnosis and management of benign prostatic hyperplasia: a review. Curr Urol Rep. 2022;23:297–302. https://doi.org/10.1007/s11934-022-01118-5.

Article  PubMed  Google Scholar 

Mossack SM, Franco A, Roadman DF, Sturgis MR, Orsini A, Bignante G, et al. Social determinants of health and surgical outcomes of minimally invasive radical prostatectomy: a national population-based study. Prostate Cancer Prostatic Dis. 2024. https://doi.org/10.1038/s41391-024-00913-0.

Narang GL, Rojanasarot S, Cutone B, Humphreys MR. Is race associated with the surgical treatment for Benign prostatic hyperplasia? an analysis of 30,000 medicare lives. J Racial Ethn Health Disparities. 2024;11:528–34. https://doi.org/10.1007/s40615-023-01538-0.

Article  PubMed  Google Scholar 

Busetto GM, Lombardo R, De Nunzio C, Santoro G, Tocci E, Schiavone N, et al. Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH. Prostate Cancer Prostatic Dis. 2024;28:37–44. https://doi.org/10.1038/s41391-024-00834-y.

Article  PubMed  Google Scholar 

Gacci M, Makrides P, Spatafora P. Impact of medical treatment on storage and voiding LUTS, nocturia, and quality of life in men at risk for progression. Prostate Cancer Prostatic Dis. 2024;27:170–1. https://doi.org/10.1038/s41391-023-00761-4.

Article  PubMed  Google Scholar 

Gemma L, Pecoraro A, Sebastianelli A, Spatafora P, Sessa F, Nicoletti R, et al. Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review. Prostate Cancer Prostatic Dis. 2024;27:404–21. https://doi.org/10.1038/s41391-024-00795-2.

Article  PubMed  Google Scholar 

Nunzio CD, Franco A, Lombardo R, Baldassarri V, Borghesi A, Marzi VL, et al. Phamacological treatment of persistant lower urinary tract symptoms after a transurethral resection of the prostate is predictive of a new surgical treatment: 10 years follow-up study. Neurourol Urodyn. 2021;40:722–7. https://doi.org/10.1002/nau.24616.

Article  PubMed  Google Scholar 

Sokolakis I, Pyrgidis N, Russo GI, Sountoulides P, Hatzichristodoulou G. Preserving ejaculation: a guide through the landscape of interventional and surgical options for Benign prostatic obstruction. Eur Urol Focus. 2022;8:380–3. https://doi.org/10.1016/j.euf.2022.03.008.

Article  PubMed  Google Scholar 

Lambertini L, Sandulli A, Coco S, Paganelli D, Cadenar A, Dell’Oglio P, et al. Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature. Prostate Cancer Prostatic Dis. 2024. https://doi.org/10.1038/s41391-024-00900-5.

Cindolo L, Rubilotta E, Kuang W, Antonelli A. When you say “Prostate”, don’t forget to say “Bladder”!. Prostate Cancer Prostatic Dis. 2024;27:5–6.

Article  PubMed  Google Scholar 

De Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol. 2003. https://doi.org/10.1016/S0022-5347(05)63949-3.

Finazzi Agrò E, Rosato E, Wagg A, Sinha S, Fede Spicchiale C, Serati M, et al. How do we make progress in phenotyping patients with lower urinary tract such as overactive bladder and underactive detrusor, including using urine markers and microbiome data, to personalize therapy? ICI-RS 2023—Part 2. Neurourol Urodyn. 2024;43:1272–82. https://doi.org/10.1002/nau.25379.

Article  CAS  PubMed  Google Scholar 

Finazzi Agrò E, Rosato E, Wagg A, Sinha S, Fede Spicchiale C, Serati M, et al. How do we make progress in phenotyping patients with LUT such as OAB and underactive detrusor, including using urine markers and microbiome data, in order to personalize therapy? ICI-RS 2023: Part 1. Neurourol Urodyn. 2024;43:1261–71. https://doi.org/10.1002/nau.25377.

Article  CAS  PubMed  Google Scholar